This mRNA vaccine could potentially prevent the deadliest form of skin cancer

Drug manufacturers Moderna and Merck say a personalized mRNA cancer vaccine plus a drug called Keytruda reduced the return and spread of melanoma in high-risk patients. Dr. Jon LaPook and trial researcher Dr. Janice Mehnert have more information.

Skin cancer breakthrough delivers second act for Moderna's mRNA vaccines  thenationalnews.com

Compared with more common skin cancers, melanoma is more likely to spread to other parts of the body.

MRNA vaccine for skin cancer succeeds in clinical trial  CNN

Pharmaceutical companies Merck, known as MSD outside the United States and Canada, and Moderna announced on Wednesday that their individualized neoantigen therapy, intismeran autogene, met its endpoints in a phase 3 trial in melanoma patients. It is the first positive result at that stage for an mRNA-based cancer treat

Moderna and Merck said the personalised vaccine reduced the risk of recurrence and spread of melanoma in a late-stage trial, a major success in a new field of cancer treatment.

Moderna and Merck said the personalised vaccine reduced the risk of recurrence and spread of melanoma in a late-stage trial, a major success in a new field of cancer treatment.

Pharmaceutical companies Moderna and Merck announced today the highly promising results of their anti-cancer mRNA vaccine Phase 3 clinical trial targeting later-stage melanoma skin cancers. Researchers sequenced the DNA from each patient's tumors to create personalized vaccines that, when injected, rev up the immune sy

The shot, paired with Merck's Keytruda, cut the risk of melanoma recurrence in a trial of more than 1,100 patients.

The results mark a step forward in the effort to treat not just melanoma but other forms of cancer with vaccines designed to help keep patients disease-free.

Moderna and Merck say the experimental vaccine prevented the return and spread of the cancer in high-risk melanoma patients.

An experimental personalized mRNA-based cancer vaccine from Merck and Moderna was successful at preventing melanoma from returning or spreading in a late-stage trial of high risk patients, the companies announced Wednesday.   The positive results mean a potentially life-extending treatment is one step closer to being a

More than 8,500 Americans are expected to die of melanoma this year